PMID- 30232238
OWN - NLM
STAT- MEDLINE
DCOM- 20190826
LR  - 20191210
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 132
IP  - 18
DP  - 2018 Sep 28
TI  - Sodium-glucose transporter 2 inhibition and cardiovascular events in patients 
      with diabetes: information from clinical trials and observational real-world 
      data.
PG  - 2003-2012
LID - 10.1042/CS20171374 [doi]
AB  - Cardiovascular (CV) disease (CVD) is the main cause of morbidity and mortality in 
      patients with type 2 diabetes mellitus (T2DM). Despite optimal glycaemic control, 
      standard antihyperglycaemic therapy failed to impact CV events in intervention 
      trials; therefore, the U.S. Food and Drug Administration (FDA) and the European 
      Medicines Agency (EMA) issued a guidance to the pharmaceutical industry to 
      specifically assess the CV outcomes and safety of new glucose-lowering drugs. 
      Amongst them, sodium-glucose transporter 2 (SGLT2) inhibitors proved to not only 
      provide good tolerance, few adverse effects, and good glycometabolic control, but 
      also striking reduction in the risk of CV events. In this review, data from the 
      main randomised controlled trials are presented, including post-hoc analyses 
      looking into several aspects of CV protection. Moreover, the main findings from 
      observational real-world studies to date are described, overall reassuring as 
      regards to CV safety and efficacy of SGLT2 inhibitors. Finally, several 
      mechanisms which might contribute to the cardioprotective effect of SGLT2 
      inhibition are depicted, including findings from recent mechanistic studies.
CI  - (c) 2018 The Author(s). Published by Portland Press Limited on behalf of the 
      Biochemical Society.
FAU - Ferrannini, Giulia
AU  - Ferrannini G
AD  - Department of Medical Sciences, Postgraduate School of Internal Medicine, 
      University of Turin, Turin, Italy giuliaferrannini89@gmail.com.
AD  - Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska 
      University Hospital Solna, Stockholm, Sweden.
FAU - Ryden, Lars
AU  - Ryden L
AD  - Cardiology Unit, Department of Medicine, Karolinska Institutet, Karolinska 
      University Hospital Solna, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180918
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Blood Glucose)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
MH  - Blood Glucose/metabolism
MH  - Cardiotonic Agents/therapeutic use
MH  - Cardiovascular Diseases/blood/*prevention & control
MH  - Diabetes Mellitus, Type 2/blood/*prevention & control
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Observational Studies as Topic/*statistics & numerical data
MH  - Outcome Assessment, Health Care/methods/statistics & numerical data
MH  - Randomized Controlled Trials as Topic/*statistics & numerical data
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - SGLT-2
OT  - cardiovascular
OT  - diabetes
EDAT- 2018/09/21 06:00
MHDA- 2019/08/27 06:00
CRDT- 2018/09/21 06:00
PHST- 2018/06/11 00:00 [received]
PHST- 2018/08/11 00:00 [revised]
PHST- 2018/08/15 00:00 [accepted]
PHST- 2018/09/21 06:00 [entrez]
PHST- 2018/09/21 06:00 [pubmed]
PHST- 2019/08/27 06:00 [medline]
AID - CS20171374 [pii]
AID - 10.1042/CS20171374 [doi]
PST - epublish
SO  - Clin Sci (Lond). 2018 Sep 18;132(18):2003-2012. doi: 10.1042/CS20171374. Print 
      2018 Sep 28.